Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 3Arthritis, Rheumatoid 3Graft vs Host Disease 2Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1Arthritis 1Anemia, Refractory 1

Interventions

fludarabine phosphate 12Mycophenolic Acid 12Cyclophosphamide 11Whole-Body Irradiation 10Cyclosporine 10Cord Blood Stem Cell Transplantation 9Peripheral Blood Stem Cell Transplantation 7Busulfan 6Tacrolimus 5Radiotherapy 5fludarabine 4Antilymphocyte Serum 4Thiotepa 3Methotrexate 3Melphalan 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Etoposide 3Cyclosporins 3sargramostim 2merphos 2Methylprednisolone 2Decitabine 2Cytarabine 2vatalanib 1poly ICLC 1lintuzumab 1entinostat 1Vorinostat 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anemia, Refractory × Abatacept × Clear all
NCT01012492 2019-11-21

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Boston Children's Hospital

Phase 2 Completed
11 enrolled 10 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Leukemia, Myelodysplastic Syndromes, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡